Post
Mercury77
#ModernaQ3VaccineSales
My take on Moderna (MRNA) Q3:
I am leaning YES on beating earnings. The bar is very low — consensus is -$1.10 EPS on ~$890M revenue, vs -$0.51 on $1.02B last year. In Q2 they already beat with -$1.97 on $145M revenue vs $103M expected.
The real story is not COVID anymore, it's the cancer vaccine data. That is why the stock is up almost 8x from its low this year.
Disclaimer: OKX Orbit content is provided for informational purposes only. Learn more
Replies
No comments yet. Be the first to reply!
